Discover trends, market shifts, and competitive outlooks for the adalimumab, infliximab and etanercept biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Estimated Market Size of the Adalimumab, Infliximab and Etanercept Biosimilars Market In 2029?
The market size of biosimilars such as adalimumab, infliximab, and etanercept has seen a significant expansion in the recent past. The market is projected to increase from a value of $4.37 billion in 2024 to $4.98 billion in 2025, showcasing a compound annual growth rate (CAGR) of 14.1%. Factors contributing to this growth during the historic period include a rise in healthcare spending, modifications in regulatory frameworks, governmental strategies, and escalating healthcare expenses.
In the coming years, the market size for biosimilars of adalimumab, infliximab and etanercept is expected to undergo swift expansion. The projected size for 2029 is approximately $7.44 billion, boasting a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this growth during the forecast period include higher healthcare spending, an aging population, and improved access to healthcare. Key trends anticipated during the forecast period encompass the launch of new products, mergers and acquisitions, formation of strategic alliances, and boost in investments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab, and etanercept biosimilars market is often stimulated by the expiration of branded drug patents. Take for instance the approval of Inflectra in the United States by the FDA, which happened after the patent on the branded drug Remicade (used for autoimmune disease treatment) expired. It was developed by Hospira, a company owned by Pfizer Inc. Similarly, the patent for Amgen’s Enbrel expired in the EU, leading to the European Commission approving Benepali, a biosimilar of Enbrel. The market also saw the introduction of Humira’s biosimilars after its patent expired, with Hulio becoming the sixth biosimilar of Humira to be approved by the FDA recently. As such, the demand for the adalimumab, infliximab, and etanercept biosimilars market is largely driven by the expiration of patents for branded biologic drugs like Humira, Enbrel, and Remicade.
Which Key Market Segments Comprise the Adalimumab, Infliximab and Etanercept Biosimilars Market and Drive Its Revenue Growth?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp
Which Areas Are Leading Regions in the Adalimumab, Infliximab and Etanercept Biosimilars Market Expansion Across the Globe?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Key Market Trends in theAdalimumab, Infliximab and Etanercept Biosimilars Market Over the Coming Years?
Leading firms in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on creating groundbreaking products such as citrate-free adalimumab to offer dependable services to their clientele. Essentially, citrate-free adalimumab is a version of the biologic drug adalimumab that excludes citrate. For example, Fresenius Kabi, a manufacturer of medicines and technologies for infusion, transfusion, and clinical nutrition based in Germany, declared its FDA approval for the biosimilar Idacio (adalimumab) for managing chronic autoimmune disorders for all allowable uses of the reference product in December 2022. The treatment was built using sophisticated analytical techniques to aid in treating a range of chronic diseases.
View the full report here:
How Is the Adalimumab, Infliximab and Etanercept Biosimilars Market Conceptually Defined?
Adalimumab, infliximab, and etanercept biosimilars refer to a novel class of medications that work to inhibit the effects of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha). A chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha) is known as an infliximab biosimilar. Immune system disorders are treated with it.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
